These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 32534273)

  • 1. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.
    Romero-Bueno F; Diaz Del Campo P; Trallero-Araguás E; Ruiz-Rodríguez JC; Castellvi I; Rodriguez-Nieto MJ; Martínez-Becerra MJ; Sanchez-Pernaute O; Pinal-Fernandez I; Solanich X; Gono T; Gonzalez-Gay MA; Plana MN; Selva-O'Callaghan A;
    Semin Arthritis Rheum; 2020 Aug; 50(4):776-790. PubMed ID: 32534273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.
    Hata K; Kotani T; Matsuda S; Fujiki Y; Suzuka T; Kiboshi T; Wada Y; Shiba H; Shoda T; Kagitani M; Takeuchi T
    Int J Rheum Dis; 2024 Jan; 27(1):e14999. PubMed ID: 38063858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.
    Tsuji H; Nakashima R; Hosono Y; Imura Y; Yagita M; Yoshifuji H; Hirata S; Nojima T; Sugiyama E; Hatta K; Taguchi Y; Katayama M; Tanizawa K; Handa T; Uozumi R; Akizuki S; Murakami K; Hashimoto M; Tanaka M; Ohmura K; Mimori T
    Arthritis Rheumatol; 2020 Mar; 72(3):488-498. PubMed ID: 31524333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
    Tokunaga K; Hagino N
    Intern Med; 2017; 56(11):1399-1403. PubMed ID: 28566605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
    Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
    Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of anti-MDA5 antibody-positive dermatomyositis developing reversible cerebral vasospasm syndrome successfully treated by multi-immunosuppressant combination including mycophenolate mofetil.
    Muramatsu T; Tono T; Kanayama Y; Hasegawa Y; Kondo J; Hoshiyama T; Wada T; Arinuma Y; Tanaka S; Yamaoka K
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):69-75. PubMed ID: 32811369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapies in anti-MDA5 antibody-positive dermatomyositis.
    Yasui M; Iwamoto T; Furuta S
    Curr Opin Rheumatol; 2024 Jan; 36(1):61-68. PubMed ID: 37682061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
    McPherson M; Economidou S; Liampas A; Zis P; Parperis K
    Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
    He C; Li W; Xie Q; Yin G
    Front Immunol; 2021; 12():820163. PubMed ID: 35116041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Emergency Lung Transplantation for Interstitial Lung Disease Associated With Anti-MDA5 Dermatomyositis: A Case Report.
    Marchiset A; Neuville M; Voiriot G; De Wolf J; Glorion M; Parquin F; Roux A; Guen ML; Allenbach Y; Zuber B; Cerf C;
    Transplant Proc; 2021 Oct; 53(8):2613-2615. PubMed ID: 34511249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
    Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
    Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
    Nandy A; Gaïni S; Sore P
    Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.
    Shirakashi M; Nakashima R; Tsuji H; Tanizawa K; Handa T; Hosono Y; Akizuki S; Murakami K; Hashimoto M; Yoshifuji H; Ohmura K; Mimori T
    Rheumatology (Oxford); 2020 Nov; 59(11):3284-3292. PubMed ID: 32276271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
    Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S
    Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606
    [No Abstract]   [Full Text] [Related]  

  • 17. Perspectives in the treatment of interstitial lung disease accompanied with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
    Tsuji H; Nakashima R; Mimori T
    Int J Rheum Dis; 2024 May; 27(5):e15201. PubMed ID: 38769940
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of autoimmune pulmonary alveolar proteinosis during the course of treatment of rapidly progressive interstitial pneumonia associated with anti-MDA5 antibody-positive dermatomyositis.
    Yatomi M; Akasaka K; Sato S; Chida M; Kanbe M; Sawada H; Yokota I; Wakamatsu I; Muto S; Sato M; Yamaguchi K; Miura Y; Tsurumaki H; Sakurai R; Hara K; Koga Y; Sunaga N; Yamakawa H; Matsushima H; Yamazaki S; Endo Y; Motegi SI; Hisada T; Maeno T
    BMC Pulm Med; 2024 Apr; 24(1):170. PubMed ID: 38589870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of anti-melanoma differentiation-associated gene 5 antibody-induced refractory dermatomyositis complicated by interstitial pneumonia using tofacitinib and its outcomes: a case report.
    Imai Y; Yorozuya T; Hatakeyama T; Nishimaki T; Takahashi T; Ishikawa T; Kondoh S; Asai Y; Mori Y; Saito A; Nishikiori H; Hosaka M; Chiba H
    J Med Case Rep; 2024 Sep; 18(1):471. PubMed ID: 39334485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.